Vnitr Lek 2006, 52(7-8):702-711

Systemic lupus erythematodes

J. Lukáč*, J. Rovenský, O. Lukáčová, D. Kozáková
Národný ústav reumatických chorôb, Piešťany, Slovenská republika, riaditeľ prof. MUDr. Jozef Rovenský, DrSc., FRCP

Systemic lupus erythematodes (SLE) is chronic autoimmune disease, characteristic by production of autoantibodies against different autoantigens. Etiopathogenesis in not precise determinated, but genetic, immunologic, hormonal factors or influence of environment are assumed. It manifests by various symptoms and it can affect whichever organ or system in the body. Clinical manifestation are due chronic inflammation in the tissues, which is caused first of all by deposit of immunocomplex and by cytotoxic damage. At the last decades the mortality of patients with SLE is markly lower and their live is prolong. In spite of this diagnostic, to follow up and therapy of this disease is complicated and it requires the colaboration of more branches of medicine.

Keywords: systemic lupus erytheamtodes; diagnostic; clinical symptoms; course; therapy

Received: May 30, 2006; Published: July 1, 2006  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Lukáč J, Rovenský J, Lukáčová O, Kozáková D. Systemic lupus erythematodes. Vnitr Lek. 2006;52(7-8):702-711.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Arnett FC. Genetics aspects of human lupus. Clin Immunol Immunopathol 1992; 63: 4-6. Go to original source... Go to PubMed...
    2. Botto M, Walport MJ. C1q, autoimmunity and apoptosis. Immunobiol 2002; 205: 395-406. Go to original source... Go to PubMed...
    3. Johnson AE, Gordon C, Palmer R et al. The prevalence and incidence of systemic lupus erythematosus in Birmingam, England. Relationship to ethnicity and country of birth. Arthritis Rheum 1995; 38: 551-558. Go to original source... Go to PubMed...
    4. Dostál C et al. Systémový lupus erytematodes. Praha: Mediprint 1997.
    5. Wallace DJ, Hahn BH (eds). Dubois'lupus erythematosus. London: William and Wilkins 1997.
    6. Cronin ME. Musculoskeletal manifestation of SLE. Rheum Dis Clin North Am 1988; 14: 99-116. Go to original source... Go to PubMed...
    7. Sontheimer RD, Gilliam JN. SLE and the skin. In: Lahita RG (ed). Systemic lupus erythematosus. New York: Churchill Livingstone 1992: 657-681.
    8. Austin HA III, Boumpas DT, Vaughan EM et al. Predicting renal outcomes in severe lupus nephritis: contributions of clinical and histological data. Kidney 1994; 45: 544-550. Go to original source... Go to PubMed...
    9. Segal AM, Calabrese LH, Ahmad M et al. The pulmonary manifestation of SLE. Semin Arthritis Rheum 1985; 14: 202-224. Go to original source... Go to PubMed...
    10. ACR AD HOC commitee on neuropsychiatric lupus nomenclature. The American College of Rheumatology nomenclature and case definitions for neuropsychatric lupus syndromes. Arthritis Rheum 1999; 42: 599-608.
    11. Venclovský J, Kafková J, Štork J. Antinukleární a anticytoplazmatické autoprotilátky u systémových revmatických onemocnení - vyšetření imunoblotingem. Čes Revmatol 1997; 5: 71-81. Go to original source...
    12. Horák P, Heřmanová Y, Faltýnek L et al. Autoprotilátkový profil a aktivita choroby u nemocných se systémovým lupus erythematodes. Vnitř Lék 1997; 43: 639-644. Go to PubMed...
    13. Tuchyňová A, Rovenský J et al. Systémový lupus erythematodes vo vyššom veku: retrospektívna štúdia. Čes Revmatol 1998; 6: 123-126.
    14. Pickering MC, Botto M, Taylor PR et al. Systemic lupus erythematosus, complement deficiency and apoptosis. Advances Immunol 2000; 76: 227-324. Go to original source... Go to PubMed...
    15. Price EJ, Venables PJW. Drug-induced lupus. Drug safety 1995; 12: 283-290. Go to original source... Go to PubMed...
    16. Tan EM et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982; 25: 1271-1277. Go to original source... Go to PubMed...
    17. Lukáč J, Rovenský J et al. Clinical characteristic of SLE with duration over the 15 years. Rheumatologia 1998; 36(Suppl): 179.
    18. Pavelka K, Lukáč J, Rovenský J et al. Výskyt salmonelózy u nemocných s generalizovaným lupus erythematodes. Vnitř Lék 1984; 30: 502-507. Go to PubMed...
    19. Rovenský J, Kovalančík M, Krištúfek P et al. Problém výskytu tuberkulózy u pacientov so systémovým lupus erythematosus. Interná medicína 2002; 10: 624-629.
    20. Sharp GC, Irvin WS et al. Mixed connective tissue disease: an apparently distinct rheumatic disease syndrome associated with a specific antibody to an extractable nuclear antigen. Am J Med 1972; 52: 148-159. Go to original source... Go to PubMed...
    21. Lukáč J, Rovenský J, Cebecauer L et al. Diagnostika a prognóza zmiešaného syndrómu spojiva (MCTD). Rheumatologia 1995; 9: 73-80.
    22. Rovenský J et al. Klinická reumatológia. Martin: Osveta 2000.
    23. Lukáč J, Rovenský J Cebecauer L et al. Intravenous versus oral cyclophosphamide therapy of systemic lupus erythematosus. Annual European Congress of Rheumatology, 12-15 June, 2002, Stockholm (Abstract): 102. Ann Rhem Dis 2002.
    24. Lukáč J, Rovenský J, Rauová L et al. Long-term cyclosporin A treatment in systemic lupus erythematosus. Int J Immunoter 1996; 14: 33-40.
    25. Dostál C, Tesař V, Rychlík I et al. Effect of 1 year cyclosporine A treatment on the activity and renal involvement of systemic lupus erythematosus: a pilot study. Lupus 1998; 7: 39-36. Go to original source... Go to PubMed...
    26. Leandro MJ, Ehrenstein MR, Edwards JCW et al. An open study of B lymphocyte depletion in systemic lupus erythematosus. Arthritis Rheum 2002; 46: 2673-2677. Go to original source... Go to PubMed...

    Return to the content


    Vnitřní lékařství

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.